Federal Grant Award Summary

Brigham & Women's Hospital Inc. received a $2.47 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period June 1, 2026 through April 30, 2031. The award supports fundamental research into neutrophil heterogeneity and immune regulation, encompassing multiple investigator-led projects designed to characterize distinct neutrophil subpopulations, their origins, functional states, and phenotypes. The research delivers scientific knowledge and methodological advances regarding how diverse neutrophil populations arise and function, with direct applications toward identifying new therapeutic targets for clinical intervention in conditions including asthma, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, cancer, and ischemia-induced tissue damage.

The project comprises four coordinated research initiatives conducted at Brigham & Women's Hospital's Boston, Massachusetts location. The research deliverables include investigations into lung interstitial neutrophil characterization, spleen-derived neutrophil antigen-presenting cell properties and trafficking mechanisms, bone marrow megakaryocyte-mediated neutrophil phenotype modulation, and additional complementary studies. These research activities generate peer-reviewed publications, experimental data, and foundational scientific understanding intended to establish specific neutrophil lineages as vehicles for targeted clinical intervention in both infectious and non-infectious inflammatory conditions.